Background and Objectives. To examine the long-term clinical course and prognostic factors of patients with advanced aggressive non-Hodgkin's lymphoma (NHL) treated with third-generation regimens as front-line chemotherapy. Design and Methods. A total of 348 patients aged <60 years received MACOP-B or F-MACHOP regimen between September 1988 and August 1993 for advanced stage aggressive NHL. Results. Of these, 249 (71.5%) obtained a complete response (CR); 65/249 (26%) subsequently relapsed. the CR rates for MACOP-B and F-MACHOP were 70.5% and 72%, respectively, while the relapse-free survival rates (RFS) at 9 years were 66% and 74%, respectively. The overall survival rate at 9 years was 61% for MACOP-B and 67% for F-MACHOP patients. Of the relapses, 78.5% were early (<24 months) and 21.5% late. Eleven out of 65 (17%) patients are in continuous second CR with a median follow-up of 45 months; most of them have been salvaged with high-dose therapies. The validity of the International Prognostic Index was confirmed in long-term analysis. Interpretation and Conclusions. With a 9-year RFS, it is possible to consider cured 50% of the patient with aggressive NHL treated with a third-generation regimen. About a quarter of the CRs relapse and late relapse occurs in roughly 20% of all relapsed patients. In these patients high-dose chemotherapy followed by autologous bone marrow or hematopoietic stem cell transplantation seems to be a very reliable approach in terms of long-term second On. Finally, the IPI score maintains its pivotal role in terms of stratifying patients according to different risk subsets also in long-term analysis. (C) 1999, Ferrata Storti Foundation.

How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term? / P. L., Zinzani; Martelli, Maurizio; M., Magagnoli; F., Zaja; S., Storti; E., Pavone; V. M., Lauta; A., De Renzo; F., Gherlinzoni; M., Bendandi; C., Cellini; Mandelli, Franco; S., Tura. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 84:11(1999), pp. 996-1001.

How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term?

MARTELLI, Maurizio;MANDELLI, Franco;
1999

Abstract

Background and Objectives. To examine the long-term clinical course and prognostic factors of patients with advanced aggressive non-Hodgkin's lymphoma (NHL) treated with third-generation regimens as front-line chemotherapy. Design and Methods. A total of 348 patients aged <60 years received MACOP-B or F-MACHOP regimen between September 1988 and August 1993 for advanced stage aggressive NHL. Results. Of these, 249 (71.5%) obtained a complete response (CR); 65/249 (26%) subsequently relapsed. the CR rates for MACOP-B and F-MACHOP were 70.5% and 72%, respectively, while the relapse-free survival rates (RFS) at 9 years were 66% and 74%, respectively. The overall survival rate at 9 years was 61% for MACOP-B and 67% for F-MACHOP patients. Of the relapses, 78.5% were early (<24 months) and 21.5% late. Eleven out of 65 (17%) patients are in continuous second CR with a median follow-up of 45 months; most of them have been salvaged with high-dose therapies. The validity of the International Prognostic Index was confirmed in long-term analysis. Interpretation and Conclusions. With a 9-year RFS, it is possible to consider cured 50% of the patient with aggressive NHL treated with a third-generation regimen. About a quarter of the CRs relapse and late relapse occurs in roughly 20% of all relapsed patients. In these patients high-dose chemotherapy followed by autologous bone marrow or hematopoietic stem cell transplantation seems to be a very reliable approach in terms of long-term second On. Finally, the IPI score maintains its pivotal role in terms of stratifying patients according to different risk subsets also in long-term analysis. (C) 1999, Ferrata Storti Foundation.
1999
aggressive nhl; f-machop; late relapses; long-term outcome; macop-b
01 Pubblicazione su rivista::01a Articolo in rivista
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens fare in the long-term? / P. L., Zinzani; Martelli, Maurizio; M., Magagnoli; F., Zaja; S., Storti; E., Pavone; V. M., Lauta; A., De Renzo; F., Gherlinzoni; M., Bendandi; C., Cellini; Mandelli, Franco; S., Tura. - In: HAEMATOLOGICA. - ISSN 0390-6078. - STAMPA. - 84:11(1999), pp. 996-1001.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/116919
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact